KIF18A inhibition and its rising role in cancer therapy trials: from bench to bedside
KIF18A inhibition represents a mechanistically grounded, tumor-selective strategy for treating CIN-driven cancers. As clinical trials progress, optimizing patient stratification and exploring synergistic combinations will be crucial. Broadening the range of druggable sites on KIF18A, especially beyond the motor domain, could mitigate resistance and help expand therapeutic potential.
Authors
- Jia Q. Truong (ORCID: https://orcid.org/0000-0002-7328-189X)
- Jessica K. Holien (ORCID: https://orcid.org/0000-0002-8735-2871)
- Tal Galper
Institutions
- MIT University (MK)
- RMIT University (AU)
Publication Details
- Journal
- Expert Opinion on Investigational Drugs
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1080/13543784.2026.2616752
- Primary Topic
- Microtubule and mitosis dynamics
- Type
- article
- Field-Weighted Citation Impact
- 0.00